Literature DB >> 2759797

Prostaglandin F2 alpha effects on intraocular pressure negatively correlate with FP-receptor stimulation.

D F Woodward1, J A Burke, L S Williams, B P Palmer, L A Wheeler, E Woldemussie, G Ruiz, J Chen.   

Abstract

According to the current working classification for prostanoid receptors, the prostaglandin F2 alpha-sensitive receptor (FP-receptor) may be identified by comparing the rank order of activity of prostaglandin F2 alpha (PGF2 alpha) and its analogues. In order to further understand the pharmacology of PGF2 alpha-induced ocular hypotension, the intraocular pressure response to PGF2 alpha and selected analogues was compared with their rank order of activity in typical FP-receptor preparations such as contraction of the cat iris sphincter and affinity for corporal luteal membrane binding sites. The rank order of potency for decreasing intraocular pressure was as follows: PGF2 alpha greater than PGF1 alpha greater than 16-phenoxytetranor PGF2 alpha greater than 17-phenyltrinor PGF2 alpha = fluprostenol (inactive). For cat iris sphincter contraction, the rank order of potency appears to be fluprostenol = 17-phenyltrinor PGF2 alpha greater than 16-phenoxytetranor PGF2 alpha = PGF2 alpha greater than PGF1 alpha. The rank order of potency for PGF2 alpha analogues in decreasing intraocular pressure appears to negatively correlate with the rank order for cat iris sphincter contraction and literature values for corporal luteal membrane binding. It is concluded that the ocular hypotensive effect of PGF2 alpha is not mediated by the FP-receptor.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2759797

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  10 in total

1.  Upregulation of orphan nuclear receptor Nur77 following PGF(2alpha), Bimatoprost, and Butaprost treatments. Essential role of a protein kinase C pathway involved in EP(2) receptor activated Nur77 gene transcription.

Authors:  Yanbin Liang; Chen Li; Victor M Guzman; William W Chang; Albert J Evinger; Jozelyn V Pablo; David F Woodward
Journal:  Br J Pharmacol       Date:  2004-05-24       Impact factor: 8.739

2.  The EP2 receptor is the predominant prostanoid receptor in the human ciliary muscle.

Authors:  T Matsuo; M S Cynader
Journal:  Br J Ophthalmol       Date:  1993-02       Impact factor: 4.638

3.  Prostanoid EP(1)- and TP-receptors involved in the contraction of human pulmonary veins.

Authors:  L Walch; V de Montpreville; C Brink; X Norel
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

Review 4.  Eicosanoid storm in infection and inflammation.

Authors:  Edward A Dennis; Paul C Norris
Journal:  Nat Rev Immunol       Date:  2015-07-03       Impact factor: 53.106

5.  Endogenous Bioactive Lipids and the Regulation of Conventional Outflow Facility.

Authors:  Zhou Wan; David F Woodward; W Daniel Stamer
Journal:  Expert Rev Ophthalmol       Date:  2008

6.  Localisation of prostaglandin F2 alpha and E2 binding sites in the human eye.

Authors:  T Matsuo; M S Cynader
Journal:  Br J Ophthalmol       Date:  1992-04       Impact factor: 4.638

7.  Identification of a prostanoid FP receptor population producing endothelium-dependent vasorelaxation in the rabbit jugular vein.

Authors:  J Chen; M L Champa-Rodriguez; D F Woodward
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

8.  Studies on a novel series of acyl ester prodrugs of prostaglandin F2 alpha.

Authors:  A Cheng-Bennett; M F Chan; G Chen; T Gac; M E Garst; C Gluchowski; L J Kaplan; C E Protzman; M B Roof; G Sachs
Journal:  Br J Ophthalmol       Date:  1994-07       Impact factor: 4.638

Review 9.  Critical evaluation of latanoprostene bunod in the treatment of glaucoma.

Authors:  Giancarlo A Garcia; Philip Ngai; Sameh Mosaed; Ken Y Lin
Journal:  Clin Ophthalmol       Date:  2016-10-18

Review 10.  The Role of Nitric Oxide in the Intraocular Pressure Lowering Efficacy of Latanoprostene Bunod: Review of Nonclinical Studies.

Authors:  Megan E Cavet; Heleen H DeCory
Journal:  J Ocul Pharmacol Ther       Date:  2017-08-07       Impact factor: 2.671

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.